This nanosubmarine could deliver sorafenib specifically to the tumor site and restore the sensitivity of hepatocellular carcinoma cells to sorafenib, demonstrating the potential of CXCR4-targeted nanoparticles for clinical applications in delivering sorafenib specifically to the tumor site and overcoming acquired drug resistance in hepatocellular carcinoma [351]. This evidence concerns the gene CXCR4 and neoplasm.